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S U M M A R Y
Objective: To review the literature in order to determine the best treatment options for multidrug-
resistant tuberculosis (MDR-TB) of the skeletal system.
Methods: We searched the PubMed database for all case reports of osteoarticular MDR-TB that provided
information on drug treatment and clinical outcome.
Results: We identiﬁed six cases with spinal MDR-TB and seven with extraspinal MDR-TB and reviewed
their susceptibility tests, treatments administered, surgical treatments, and clinical outcomes. All
patients had a successful clinical outcome (either cured or improved) except one who died due to
septicemia. One patient with spinal MDR-TB and four patients with extraspinal MDR-TB had a successful
outcome with medical treatment alone. Two patients who received treatment for a shorter time or with
fewer drugs than recommended were cured with the addition of surgery.
Conclusions: Osteoarticular MDR-TB is very infrequently reported in the literature. The few cases
reviewed suggest that it is possible to achieve a good outcome with second-line anti-tuberculous drugs,
and that surgery might be useful for cases in which an optimized medical treatment is not possible.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The skeletal system can be involved in 1–3% of tuberculosis
cases.1 Spinal tuberculosis is the most common form, affecting the
vertebral bodies and intervertebral discs. Extraspinal tuberculosis
can cause osteomyelitis or arthritis in any peripheral bones or
joints.1
Multidrug-resistant tuberculosis (MDR-TB), deﬁned as resis-
tance to isoniazid and rifampin, is an important public health
problem, with increasing incidence worldwide.2 Guidelines for the
treatment of MDR-TB have been published.3–5 However, they are
based mainly on pulmonary MDR-TB and none of them give any
recommendations for the treatment of osteoarticular forms. There
is very little evidence to guide the drug treatment of osteoarticular
MDR-TB: no review on the subject has yet been published, and the
case reports in the literature are very few. In addition, the efﬁcacy
of many second-line anti-tuberculous drugs in the bone is not well
known. The treatment of osteoarticular MDR-TB is thus a major
challenge.
We performed a systematic review of all cases reported in the
literature with osteoarticular MDR-TB (spinal and extraspinal),
with the aims of assessing the options for treatment (medical and/* Corresponding author. Tel.: +34 91 191 4133; fax: +34 91 191 5013.
E-mail address: inessuarez@hotmail.com (I. Sua´rez-Garcı´a).
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http://dx.doi.org/10.1016/j.ijid.2012.07.011or surgical) and determining what drug treatment options could be
more likely to achieve a successful clinical outcome.
2. Materials and methods
We searched the PubMed database using the terms ‘‘multidrug-
resistant tuberculosis’’, ‘‘osteomyelitis’’, ‘‘osteoarticular’’, ‘‘spon-
dylitis’’, ‘‘spondylodiscitis’’, ‘‘spinal’’, and ‘‘arthritis’’. Articles in any
language except Chinese were included if they reported cases with
arthritis or osteomyelitis (spinal or extraspinal) due to MDR-TB
conﬁrmed with drug-susceptibility testing, and provided informa-
tion on drug therapy, surgical therapy, and treatment outcome.
Whenever follow-up was not available at or after the end of
treatment, at least a report of the interim outcome during
treatment was required.
We included articles reporting more than one case if the
variables of interest were reported on an individual basis.
Additional cases were identiﬁed from the references of the articles
included. Case reports with resistance other than MDR were not
included.
The following variables were recorded for each case: year of
publication, age, sex, treatment delay (deﬁned as the time from the
ﬁrst symptom to the start of effective MDR-TB treatment), HIV
serology, presence of diseases or treatments associated with
immunosuppression, bones or joints involved, other organs (in
addition to bones or joints) affected by tuberculosis, drugses. Published by Elsevier Ltd. All rights reserved.
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continuation phases, duration of treatment, side effects of
treatment, surgery, institution of directly observed treatment,
time of follow-up, death and cause of death, clinical evolution, and
means of assessing cure.
We recorded only the information related to the MDR-TB:
previous history and treatments of drug-sensitive strains were
ignored. Side effects were only considered if they caused a drug to
be withdrawn. Surgery was recorded only if it was done for
therapeutic purposes, and we excluded surgery done solely for
diagnostic purposes (surgical biopsies or needle aspiration). We
considered that a patient had undergone directly observed
treatment if the case report explicitly stated that the treatment
was administered either as an inpatient or supervised by any
institution or family members. Time of follow-up was calculated
from the beginning of treatment for MDR-TB. Patients were
considered cured if there was clinical improvement without
evidence of active disease at treatment completion. Patients were
considered improved when follow-up information was not
available at the end of treatment (due to loss to follow-up or
publication before the end of treatment) but there was clinical
improvement while on treatment.
3. Results
We found eight case reports of spinal MDR-TB and eight of
extraspinal skeletal MDR-TB. One case was excluded because the
diagnosis of MDR-TB was done after death,6 and another was
excluded because the patient was lost to follow-up 10 weeks after
the start of treatment and no information on the outcome of the
bone lesion was reported.7 One case was identiﬁed by the abstract
published in PubMed, but the complete article providing
information on treatment and clinical outcome was irretrievable
and so this case was excluded.8 In addition, we retrieved two series
of 25 cases9 and seven cases10 with spinal MDR-TB, which were
excluded because they did not report information on drug
treatment on an individual basis. Finally, we included six patients
with vertebral osteomyelitis and seven patients with extraverteb-
ral osteomyelitis, whose cases were published between the years
1997 and 2012.
Clinical characteristics, susceptibility testing, treatments ad-
ministered, and outcomes of the 13 patients are shown in the Table
1.11–23 Five patients were male and eight were female. Four
patients were aged 12 years or younger. None had an HIV infection
(eight had negative serology and ﬁve had no report of the result),
but four had other immunosuppressive conditions: two had
diabetes mellitus,15,23 one had end-stage renal disease,20 and one
had rheumatoid arthritis treated with steroids and cyclophospha-
mide.19
Eight cases were followed for a length of time sufﬁcient to allow
assessment of cure, and ﬁve cases were published before the end of
treatment providing only information on the interim outcome.
With the exception of one patient who died of septicemia, all of the
other patients were either cured or improved. Eight patients
underwent surgery for abscess drainage, debridement, or vertebral
stabilization, and ﬁve patients improved or were cured with
medical treatment alone. None of the patients with spinal MDR-TB
were reported to have any neurological compromise. No sequelae
were reported after treatment of spinal MDR-TB except for one
patient who had residual scoliosis.16 Seven patients were placed on
directly observed treatment, and six did not report whether the
treatment was supervised.
Drug treatments were very heterogeneous. Ten patients
received at least four drugs to which the isolate was likely to be
susceptible. One patient22 received only two drugs likely to be
effective, as he had been treated with effective monotherapy ordual therapy with ethambutol and cycloserine during the previous
months; however, the patient was cured after surgery and 12
months with only one drug not previously used. Two patients
received only three anti-tuberculous drugs: one was cured with
surgery and the other was cured without surgery.
Excluding the patient who died and the patient who received
only two drugs likely to be effective, all of the other patients had at
least 11 months of drug therapy except one, whose treatment was
withdrawn after 5 months due to toxicity.13 This patient
underwent surgical substitution of the affected vertebra and
was cured.
4. Discussion
Our review shows that there are very few case reports
published that provide information on drug treatment for
osteoarticular MDR-TB. Also, a good proportion of them did not
have a sufﬁcient follow-up time to assure complete cure of the
disease. However, an analysis of the few available cases could
provide some useful information for clinicians facing the challenge
of treating MDR-TB of the bone. This condition is likely to be more
frequently encountered in the future as the incidence of MDR-TB
keeps increasing.2 Except for one patient who died of septicemia,
all the cases reviewed were cured or improved with drug
treatment including at least four drugs to which the isolate was
likely to be susceptible (or even three drugs for two cases). For the
two patients who were more likely to experience therapeutic
failure (one with only 5 months of treatment and the other with
only two drugs likely to be effective), it appears that cure was
achieved by surgical removal of the infected tissue. Thus, in spite of
the scarce information available, it seems that cure can be achieved
by following the general guidelines for the treatment of MDR-TB
and, for cases in which not enough second-line drugs can be
administered or the length of treatment is shorter than recom-
mended, cure could still be possible with the aid of surgery.
The World Health Organization (WHO) guidelines for the
treatment of MDR-TB, aimed mainly at pulmonary forms,
recommend the use of at least four anti-tuberculosis drugs with
either certain, or almost certain, effectiveness.3,4 The 2011 update
increased the recommended treatment time to a minimum of 8
months for the injectable agent and 20 months for total treatment
time, and recommended that the treatment should include
pyrazinamide, a ﬂuoroquinolone, a parenteral agent, ethionamide
(or prothionamide), and cycloserine, or else p-aminosalicylic acid
(PAS) if cycloserine cannot be used.3 These guidelines do not
provide speciﬁc recommendations for osteoarticular MDR-TB.
Most of the patients in our review had a total treatment time of 18–
24 months. In addition to the lack of information on the best
therapeutic approach, bone tuberculosis poses the additional
difﬁculty of obtaining follow-up samples of the lesions to assess
culture conversion.
The treatment of non-resistant osteoarticular tuberculosis is
mainly medical. In spinal non-resistant TB, the role of surgery is
restricted to neurological deﬁcits due to compression of the spinal
cord, spinal instability, progression despite adequate drug therapy,
drainage of large paraspinal abscesses, and the correction of
deformities;1,24 there is no evidence to support routine surgery in
addition to chemotherapy for patients without any of these
conditions.25 Likewise, non-resistant extraspinal TB is treated
medically, and surgery is reserved for failure of medical treatment
or correction of deformed or destroyed joints.26–29 Whether
surgery might be needed more frequently for osteoarticular
MDR-TB is unknown. In our review, all patients with spinal
MDR-TB had indications for surgery except one, who was cured
only with medical treatment.12 The only death in the series might
have been due to surgical complications, as the patient had
Table 1
Clinical characteristics, susceptibility testing, treatments administered, and outcomes of our patient and the 12 patients reported in the literature.
Ref. Age/
sex
Treatment
delay
Bones affected Other organs
affected
Antibiogram Treatmenta Surgery Last
follow-up
Assessment of cure
Spinal
11 32/F 12 m C6–D2 No Resistant: H, R, Z
Susceptible: E, S, Am, Lfx,
Eto, Cs, PAS
3 Am–E–Lfxb–Eto–Cs/
15 E–Mfx–Eto–Cs
C7 vertebrectomy and
substitution
46 m Clinical and radiological
resolution
12 23/M NS Vertebral bodies T4–T6,
T9–S2, S4
Paravertebral
abscess, lung
Resistant: H, R, Z, S, Pto
Susceptible: E, Am, Cm,
Cfx, Mfx, Cs, PAS, Lzd
6 Am–E–Mfx–Cs–Lzd/
5 E–Mfx–Cs–Lzd
(intended total 24 m)c
No 11 mc Radiological improvement,
resolution of symptoms
13 49/F 18 m Vertebral body T8,
disc T8–T9
No Resistant: H, R
Susceptible: NS
2 S–E–Z–Ofx–Cs/
3 Eb–Zb–Ofxb–Csb
D8 vertebrectomy and
substitution, stabilization
4.5 y Resolution of symptoms,
normal ESR
14 12/M 8 m Skull base, C1 Prevertebral
abscesses, lung
Resistant: H, R, E, Z, S, Cs,
Clr
Susceptible: Km, Eto, PAS, Cfz
Moderately susceptible:
Cfx, Ofx
11 Km–Ofx–Eto–PAS–Cfz
(intended total 24 m)c
Drainage of abscesses,
halo traction
11 mc Resolution of symptoms
15 68/F 2 y L4 vertebral body,
L3 posterior arch,
discs L3–L4 and L4–L5
Psoas abscess,
epiduritis
Resistant: H, R, E, Z
Susceptible: S, Km, Am,
Ofx, Eto, PAS, Cfz, Clr
3 Zb–Ofx–Eto–Cfz–Clr/
2 Ofx–Eto–Cfz–Clr
Abscess drainage, spinal
cord decompression
5 m Death due to septicemia
16 27/M 6 m C7, L1 Paravertebral
abscesses
Resistant: H, R, S
Susceptible: NS
2 Am–E–Mfx–Cs/
16 E–Mfx–Cs
Abscess drainage,
stabilization
24 m Clinical recovery, residual
scoliosis
Extraspinal
17 9 m/M 4 m Left femoral neck and
epiphysis
No Resistant: all ﬁrst-line
Susceptible: NS
4 Cm–Eto–Cs/
14 Eto–Cs
No 42 m Resolution of symptoms,
femur growth (leg slightly
shorter)
18 4/F 12 m Right ankle arthritis,
subchondral cortical
surfaces of right
tibio-talar bones
Lung Resistant: H, R, S
Susceptible: E, Z, Km,
Ofx, Eto, Cs, PAS
12 E–Z–Eto–Cs–PAS
(intended total 24 m)c
No 12 mc Healing of talar erosion,
normal gait; mild limitation
in ankle motion
19 40/F 6 m Destruction of right
coxofemoral joint
Cutaneous ﬁstula,
lung
Resistant: H, R, Km, Am
Susceptible: Cfx, Ofx, Cs,
PAS, Cfz
Inconsistently susceptible:
S, E
12 E–Ofx–Cs–PASb No 12 m Partial radiologic improvement;
walking with cane
20 40/F 4 m Destruction of right tibial
plateau and articular
cartilage
Knee periarticular
abscesses, gluteal
abscesses
Resistant: H, R, E, S
Susceptible: Z, Am,
quinolones
2 Amb–Z–Ofx/
10 Z–Ofx
Knee debridement
and abscess drainage
48 m Clinical and radiological
resolution
21 58/F Several m Lytic image in 5th right
metacarpal metaphysis
Cutaneous ﬁstula Resistant: H, R
Susceptible: NS
2 Ab–E–Z–Ofx/
10 Eb–Z–Ofx/
6 Z–Ofx
(intended total NS)c
Debridement 18 mc Clinical improvement (no
suppuration, functional
improvement)
22 6/M 15 m Destruction of left
mastoid
Otitis Resistant: H, R, Z, S
Susceptible: E, Cm,
Eto, Cs
3 H–R–E–S/
3 H–E–Cs/
2 E–Z–Ofx/
10 E–Eto–Cs
Left mastoidectomy 36 m Complete clinical recovery
(sequela of hearing loss)
23 47/F 3 y Left metatarsals Left foot ulcer Resistant: H, R
Susceptible: NS
6 Km–E–Z–Ofx–Eto–PAS/
18 E–Ofx–Eto–PAS
No 24 m Complete wound healing
ESR, erythrocyte sedimentation rate; F, female; m, months; M, male; NS, not speciﬁed; y, years.
Drug abbreviations: Am, amikacin; Cfx, ciproﬂoxacin; Cfz, clofazimine; Clr, clarithromycin; Cm, capreomycin; Cs, cycloserine; E, ethambutol; Eto, ethionamide; H, isoniazid; Km, kanamycin; Lfx, levoﬂoxacin; Lzd, linezolid; Mfx,
moxiﬂoxacin; Ofx, oﬂoxacin; PAS, p-aminosalicylic acid; Pto, protionamide; R, rifampin; S, streptomycin; Z, pyrazinamide.
a Treatments are shown as number of months followed by drugs administered in each phase. Different phases are divided by ‘/’.
b Discontinued due to toxicity.
c Published before the end of treatment.
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patients were cured or improved with medical treatment alone,
and three patients needed surgery (one of these because of failure
of medical therapy with only two drugs likely to be effective22).
This suggests that skeletal MDR-TB can be treated medically and
that indications for surgery would probably be the same as for non-
resistant tuberculosis.
There is very little evidence in the literature to assess the
efﬁcacy of second-line anti-tuberculous drugs in the bone.
Ethambutol and pyrazinamide have adequate concentrations in
vertebral bone lesions, although the concentration in sclerotic
lesions might be suboptimal.30,31 Streptomycin and ethambutol
penetrate well into synovial ﬂuid and skeletal cold abscesses.32
Linezolid and quinolones are particularly interesting for the
treatment of tuberculous osteomyelitis as they penetrate well
into bone tissue and have been extensively used for the treatment
of other types of bacterial osteomyelitis.33–35 Even though the
evidence for the use of linezolid in MDR-TB is small and therefore it
is not included as a ﬁrst choice in the WHO guidelines, it is
increasingly been used and its effectiveness seems to be
adequate.36–38 Although we found no studies assessing amikacin
or kanamycin, other aminoglycosides have good penetration in
synovial ﬂuid and intervertebral discs.39,40 In view of the paucity of
data to guide the choice of the most active drugs on bone tissue, it
seems reasonable to follow the published guidelines for the
treatment of pulmonary MDR-TB.3–5
The main limitations of our review are the small number of
cases and the insufﬁcient follow-up time reported in some of them.
We chose to include the patients with an incomplete follow-up
time as long as they reported an interim outcome to assess at least
improvement, because we thought this information would also be
valuable in view of the paucity of reports available. There is the
possibility of a publication bias which would prevent cases with an
unsuccessful outcome being published; however one would expect
that these cases might still be reported due to the rarity of this
condition, as was the case with one of our excluded cases
diagnosed at autopsy.6
In conclusion, there is little evidence to guide the treatment of
osteoarticular MDR-TB. There are very few published cases and in
many publications the focus is on surgical treatment, with very
little or no information on drug therapy. The small number of cases
found in our review prevents us from drawing ﬁrm conclusions.
However, in spite of the difﬁculties it appears that most cases can
be successfully treated. In our opinion, it seems reasonable to
follow the general guidelines for the treatment of MDR-TB,3–5
bearing in mind that quinolones and linezolid are good choices for
the treatment of bone infections. The indications for surgery in
skeletal MDR-TB should probably be the same as for non-resistant
tuberculosis. It is possible to achieve a successful outcome with
medical treatment, which must be concordant with published
guidelines. However, when the administration of an adequate
number of drugs in accordance with the guidelines is not possible
(due to toxicity or multiple resistance to second-line drugs), cure
might be achieved with surgical debridement in spite of
suboptimal medical therapy.
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